Systems Immunity Research Institute, Cardiff University, Cardiff, UK.
Immunology Network, Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK.
Immunology. 2021 Jun;163(2):128-144. doi: 10.1111/imm.13300. Epub 2021 Jan 25.
Dysfunction of the immune system underlies a plethora of human diseases, requiring the development of immunomodulatory therapeutic intervention. To date, most strategies employed have been focusing on the modification of T lymphocytes, and although remarkable improvement has been obtained, results often fall short of the intended outcome. Recent cutting-edge technologies have highlighted macrophages as potential targets for disease control. Macrophages play central roles in development, homeostasis and host defence, and their dysfunction and dysregulation have been implicated in the onset and pathogenesis of multiple disorders including cancer, neurodegeneration, autoimmunity and metabolic diseases. Recent advancements have led to a greater understanding of macrophage origin, diversity and function, in both health and disease. Over the last few years, a variety of strategies targeting macrophages have been developed and these open new therapeutic opportunities. Here, we review the progress in macrophage reprogramming in various disorders and discuss the potential implications and challenges for macrophage-targeted approaches in human disease.
免疫系统功能障碍是多种人类疾病的基础,这需要开发免疫调节治疗干预措施。迄今为止,大多数采用的策略都集中在修饰 T 淋巴细胞上,尽管已经取得了显著的改善,但结果往往达不到预期。最近的前沿技术强调了巨噬细胞作为疾病控制的潜在靶点。巨噬细胞在发育、稳态和宿主防御中发挥核心作用,它们的功能障碍和失调与多种疾病的发生和发病机制有关,包括癌症、神经退行性疾病、自身免疫和代谢疾病。最近的进展使人们对健康和疾病中巨噬细胞的起源、多样性和功能有了更深入的了解。在过去的几年中,已经开发出了多种针对巨噬细胞的策略,这些策略为治疗带来了新的机会。在这里,我们综述了在各种疾病中巨噬细胞重编程的进展,并讨论了针对人类疾病的巨噬细胞靶向方法的潜在意义和挑战。